• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Intraday Session

    4/29/24 12:31:20 PM ET
    $ADXN
    $ANVS
    $AQST
    $CLDI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ADXN alert in real time by email

    Gainers

    • Deciphera Pharmaceuticals (NASDAQ:DCPH) stock moved upwards by 72.2% to $25.22 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion.
    • Calidi Biotherapeutics (AMEX:CLDI) shares rose 51.46% to $0.24. The market value of their outstanding shares is at $11.9 million.
    • SINTX Techs (NASDAQ:SINT) stock moved upwards by 32.17% to $0.05. The market value of their outstanding shares is at $6.5 million.
    • Koninklijke Philips (NYSE:PHG) stock moved upwards by 28.02% to $26.98. The company's market cap stands at $24.4 billion. As per the news, the Q1 earnings report came out today.
    • Phibro Animal Health (NASDAQ:PAHC) shares rose 26.94% to $16.16. The market value of their outstanding shares is at $654.5 million.
    • Soleno Therapeutics (NASDAQ:SLNO) shares rose 25.36% to $47.5. The company's market cap stands at $1.5 billion.

    Losers

    • Annovis Bio (NYSE:ANVS) stock declined by 57.7% to $7.62 during Monday's regular session. The company's market cap stands at $83.9 million.
    • Addex Therapeutics (NASDAQ:ADXN) shares decreased by 49.07% to $8.2. The market value of their outstanding shares is at $8.7 million.
    • SELLAS Life Sciences Gr (NASDAQ:SLS) shares fell 16.44% to $1.22. The company's market cap stands at $68.6 million.
    • Strata Skin Sciences (NASDAQ:SSKN) stock fell 15.69% to $0.43. The company's market cap stands at $15.2 million.
    • Assure Hldgs (NASDAQ:IONM) shares declined by 15.41% to $0.59. The market value of their outstanding shares is at $5.2 million.
    • Aquestive Therapeutics (NASDAQ:AQST) stock decreased by 13.15% to $3.54. The market value of their outstanding shares is at $318.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ADXN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADXN
    $ANVS
    $AQST
    $CLDI

    CompanyDatePrice TargetRatingAnalyst
    Koninklijke Philips N.V. NY Registry Shares
    $PHG
    12/17/2025Sector Perform
    RBC Capital Mkts
    Soleno Therapeutics Inc.
    $SLNO
    11/18/2025$75.00Outperform
    Wolfe Research
    Soleno Therapeutics Inc.
    $SLNO
    10/7/2025$125.00Buy
    Goldman
    Soleno Therapeutics Inc.
    $SLNO
    8/20/2025$123.00Overweight
    Wells Fargo
    Phibro Animal Health Corporation
    $PAHC
    7/7/2025$35.00Neutral → Overweight
    Analyst
    Soleno Therapeutics Inc.
    $SLNO
    6/23/2025$110.00Buy
    TD Cowen
    Phibro Animal Health Corporation
    $PAHC
    6/16/2025$24.00Underperform → Neutral
    BNP Paribas Exane
    Aquestive Therapeutics Inc.
    $AQST
    6/2/2025$7.00Outperform
    Oppenheimer
    More analyst ratings

    $ADXN
    $ANVS
    $AQST
    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    CHIEF FINANCIAL OFFICER Fulk Jennifer was granted 39,200 shares (SEC Form 4)

    4 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    3/4/26 5:59:56 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form 3 filed by new insider Fulk Jennifer

    3 - SOLENO THERAPEUTICS INC (0001484565) (Issuer)

    3/4/26 5:58:24 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADXN
    $ANVS
    $AQST
    $CLDI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

    Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

    4/29/24 7:48:13 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ANVS
    $AQST
    $CLDI
    SEC Filings

    View All

    SEC Form 424B5 filed by Calidi Biotherapeutics Inc.

    424B5 - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    3/6/26 8:38:07 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-3MEF filed by Calidi Biotherapeutics Inc.

    S-3MEF - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    3/5/26 9:59:34 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed by Strata Skin Sciences Inc.

    EFFECT - STRATA Skin Sciences, Inc. (0001051514) (Filer)

    3/5/26 12:15:03 AM ET
    $SSKN
    Medical/Dental Instruments
    Health Care

    $ADXN
    $ANVS
    $AQST
    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    RBC Capital Mkts initiated coverage on Philips

    RBC Capital Mkts initiated coverage of Philips with a rating of Sector Perform

    12/17/25 9:26:42 AM ET
    $PHG
    Medical Electronics
    Health Care

    Wolfe Research initiated coverage on Soleno Therapeutics with a new price target

    Wolfe Research initiated coverage of Soleno Therapeutics with a rating of Outperform and set a new price target of $75.00

    11/18/25 8:27:59 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Goldman initiated coverage on Soleno Therapeutics with a new price target

    Goldman initiated coverage of Soleno Therapeutics with a rating of Buy and set a new price target of $125.00

    10/7/25 9:49:14 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $ADXN
    $ANVS
    $AQST
    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Philips connects patient monitoring and diagnostics to advance platform-based care intelligence at HIMSS26

    March 10, 2026 Amsterdam, the Netherlands, and Las Vegas, USA – Royal Philips (NYSE:PHG, AEX: PHIA)), a global leader in health technology, today highlighted how open, interoperable, AI-enabled platforms can help health systems connect continuous patient monitoring with diagnostic insights – bringing the patient story together across time and across specialties. By connecting clinical signals with diagnostic information, Philips enables care teams to move from fragmented data to a more continuous, actionable understanding of the patient. Health systems are under unprecedented pressure, with rapidly growing data volumes stretching clinical capacity and contributing to care delays. Delays ar

    3/10/26 11:00:00 AM ET
    $PHG
    Medical Electronics
    Health Care

    Calidi Biotherapeutics Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Underwriters' Over-Allotment Option

    SAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today announced the closing of its previously announced underwritten public offering and the exercise in full of the underwriters' over-allotment option for gross proceeds of approximately $6.0 million, prior to deducting underwriting commissions and offering expenses. In connection with the offering, the Company sold 12,094,631 shares of common stock (or pre-funded warrants in lieu thereof) Series J warrants to purchase 12,094,631 shares of common stock, Series K warrants to purchase 12,094,63

    3/9/26 8:50:07 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

    WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced an inducement grant for Matthew Greenhawt, MD, MBA, MSc, Chief Medical Officer of Aquestive Therapeutics (the "Company"), under the Company's 2022 Equity Inducement Plan. The inducement grant was approved by the Company's Compensation Committee. Under the Company's 2022 Equity Inducement Plan, Dr. Greenhawt will receive an equity award of 75,000 Restricted Stock Units (the "Inducement RSUs") and an equit

    3/9/26 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ANVS
    $AQST
    $CLDI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lyons Christopher Michael bought $24,092 worth of shares (8,292 units at $2.91) (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    3/10/26 9:00:18 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $ADXN
    $ANVS
    $AQST
    $CLDI
    Financials

    Live finance-specific insights

    View All

    Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    Reaffirms guidance to resubmit Anaphylm™ (dibutepinephrine) sublingual film NDA in Q3 2026; Type A meeting with FDA expected to occur within 30 daysOn track to submit regulatory applications for Anaphylm in Canada and the EU in 2026Extends revenue sharing agreement with RTW to June 30, 2027Excluding one-time items, meets 2025 guidance for revenue and non-GAAP adjusted EBITDA lossGuides to end FY2026 with cash and cash equivalents of $70 millionCompany to host investment community conference call on March 5, 2026 WARREN, N.J., March 04, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring m

    3/4/26 4:01:00 PM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT™ XR

    REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and full-year ended December 31, 2025 and provided an update on the U.S. launch of VYKAT™ XR (diazoxide choline) extended-release tablets. Fourth Quarter and Full-Year 2025 and Recent Corporate Highlights Revenue, net, from the sale of VYKAT XR for the three and twelve months ended December 31, 2025, was $91.7 million and $190.4 million, respectively.From approval on March 26, 2025 through December 31, 2025, Soleno reports: 1,250 patien

    2/25/26 4:01:00 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET

    WARREN, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2025 and provide an update on recent developments in its business after market close on Wednesday, March 4, 2026. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, March 5, 2026. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webc

    2/24/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ANVS
    $AQST
    $CLDI
    Leadership Updates

    Live Leadership Updates

    View All

    Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

    REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Officer, succeeding James Mackaness, who announced that he will be retiring from the Company by the end of the first quarter. Mr. Mackaness will serve as a consultant to Soleno through the end of the year to ensure a smooth transition. Mrs. Fulk brings to Soleno more than two decades of public company experience in leading financial strategy, investor relations, financial reporting, and operational efficiency, with a diverse c

    2/26/26 8:00:00 AM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

    Board-certified allergist and leading food allergy and anaphylaxis researcher joins Aquestive to support Anaphylm™ (dibutepinephrine) sublingual film NDA resubmission and pipeline WARREN, N.J., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Matthew Greenhawt, MD, MBA, MSc, as Chief Medical Officer, strengthening its leadership team as the Company prepares to resubmit its Anaphylm™ New Drug Application (NDA) to the United Stated Food and Drug Admi

    2/18/26 7:00:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADXN
    $ANVS
    $AQST
    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Soleno Therapeutics Inc.

    SC 13D/A - SOLENO THERAPEUTICS INC (0001484565) (Subject)

    11/19/24 9:44:27 PM ET
    $SLNO
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Amendment: SEC Form SC 13D/A filed by Phibro Animal Health Corporation

    SC 13D/A - PHIBRO ANIMAL HEALTH CORP (0001069899) (Subject)

    11/15/24 4:15:40 PM ET
    $PAHC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care